Details for Patent: 9,951,016

Which drugs does patent 9,951,016 protect, and when does it expire?

Patent 9,951,016 protects AKYNZEO and is included in one NDA.

This patent has eight patent family members in eight countries.

Summary for Patent: 9,951,016

Patent landscape, scope, and claims:

Title:	Crystalline forms of an NK-1 antagonist
Abstract:	The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
Inventor(s):	Bacilieri; Christian (Breganzona, CH), Frasca; Gionata (Minusio, CH)
Assignee:	HELSINN HEALTHCARE SA (Lugano/Pazzallo, CH)
Application Number:	14/865,370
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 9,951,016

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	9,951,016		Y	Y

International Family Members for US Patent 9,951,016

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015323515
Canada	2960599
China	107001275
European Patent Office	3197871
Japan	2017529380